Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Early Phase 1UnknownNCT06249633

Yuri Matusov20 enrolled

Overview

Open-label pilot study of early inhaled nitric oxide (iNO) for patients developing de novo pulmonary hypertension during Acute Respiratory Distress Syndrome (ARDS.) The study aims to determine whether iNO has possible hemodynamic and clinical benefits when given early in the course of ARDS to patients with evidence of elevated pulmonary artery pressure.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acute Respiratory Distress Syndrome Pulmonary Hypertension

Interventions

Nitric OxideDRUG

Inhaled nitric oxide

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of ARDS based on the Berlin criteria * Mechanically ventilated * Age ≥ 18 years Exclusion Criteria: * Primary cardiogenic shock * History of more than mild pulmonary hypertension preceding ARDS diagnosis * Presence of pre-existing significant valvular disease * Presence of pre-existing left ventricular dysfunction or significant hypertrophy * Consent cannot be obtained from the patient or his/her surrogates * Refusal of consent * Opinion of treating physicians that enrolling the patient in the study would be detrimental to his/her outcome

Locations (1)

Cedars-Sinai Medical Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Determining improvement in pulmonary artery pressure in response to iNO

Pulmonary artery systolic pressure (in mmHg) will be determined by repeat echocardiography after initiation of iNO.